Telomir Pharmaceuticals Announces Publication of Preclinical Telomir‑Zn Study

What Happened
On August 10, 2026 Telomir Pharmaceuticals (TELO) announced the publication of a peer‑reviewed preclinical study in the Journal of Oncology Research and Therapy (Vol. 11, Issue 3) titled “Telomir‑Zn Modulates Intracellular Iron and Copper to Inhibit JmjC Histone Demethylases and Suppress Tumor Growth in Prostate and Triple‑Negative Breast Cancer.” The paper reports that Telomir‑Zn inhibits JmjC histone demethylases (KDMs) by depleting free intracellular iron, leading to reduced primary tumor growth in prostate and triple‑negative breast cancer (TNBC) models and significantly reduced metastatic spread in an HCC1806 TNBC model. The study also showed reactivation of silenced tumor‑suppressor genes in a prostate model and synergistic tumor reduction when Telomir‑Zn was combined with paclitaxel in TNBC models.

Key Details

• Announcement filed on Form 8‑K under Item 7.01 (Regulation FD disclosure) on August 10, 2026; study published in Journal of Oncology Research and Therapy, Vol. 11, Issue 3.
• Mechanism: Telomir‑Zn inhibits KDM histone demethylases by depleting free intracellular iron; TNBC iron‑rescue experiments supported mechanism specificity.
• Efficacy signals: reduced primary tumor growth in prostate and TNBC models; significant reduction in metastatic dissemination in the HCC1806 TNBC model.
• Combination potential: Telomir‑Zn + paclitaxel produced synergistic tumor reduction in TNBC preclinical models.

Why It Matters
For investors, the filing highlights positive preclinical evidence for Telomir‑Zn’s anti‑cancer activity, including a rare preclinical signal on metastasis reduction and potential for combination therapy with chemotherapy (paclitaxel). These findings may support further development decisions and raise the program’s scientific profile. However, the company’s 8‑K is a Regulation FD disclosure (furnished, not filed) and includes standard forward‑looking disclaimers — these are preclinical results and do not guarantee safety, efficacy, regulatory approval, or commercial success.